Daniel Leonard, DO
Pulmonary Disease · Appleton, WINPI 1366671489
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 80.7% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $4,620, more than ten times the $36 reported in 2019.
Across 50 payments — averaging $102.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$385
- Grifols USA, LLC$119
- Sanofi$111
- Philips North America LLC$95
- AstraZeneca$70
- plus $210 from 4 others
Across 86 payments — averaging $8297.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$714K
What the payments were for
- Travel & lodging$1,62632%
- Food & beverage$98919%
- Education$2,50049%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $4,126 |
| GSK | 18 | $385 |
| Grifols USA, LLC | 4 | $119 |
| Sanofi | 5 | $111 |
| Philips North America LLC | 5 | $95 |
| AstraZeneca | 3 | $70 |
| Boehringer Ingelheim | 3 | $65 |
| Amgen | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,066
How this compares
$5,115 in reported general payments places this provider in the 75th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 27 | $350,599 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $24,430 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $15,235 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $13,471 |
| Spiriva RespimatTiotropium Bromide | 14 | $10,454 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $9,738 |
| Arnuity ElliptaFluticasone Furoate | 37 | $8,473 |
| DuleraMometasone/Formoterol | 18 | $6,577 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $6,418 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 69 | $1,700 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,288 |
| Montelukast Sodium | 11 | $13 |
| Prednisone | 21 | $12 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $65 | $367,47153 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $385 | $57,877115 claims |
| AstraZenecaBreztri Aerosphere | $70 | $13,47120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Appleton
- Scott ParrishAppleton$12K
- Nicholas FreemanAppleton$10K
- Sanjeevkumar PatelAppleton$6K
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
- Alfred HabelKenosha$194K
- Manar Al ShahrouriGreen Bay$61K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.